Path_MSH6 variants are associated with a lower penetrance of CRC than MLH1 and MSH2 and an increased risk of endometrial cancer in females [35]; these characteristics could affect the identification of path_MSH6 carrier families in our registry based on LS clinical criteria. This evidence concerns the gene MSH2 and endometrial cancer.